



Atty. Dkt. No. 038602-1220

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Peng-Cho TANG, et al.

Title: INDOLINONE COMBINATORIAL LIBRARIES
AND RELATED PRODUCTS AND METHODS
FOR THE TREATMENT OF DISEASE

Appl. No.: 09/897,755

Filing Date: 07/03/2001

Examiner: Not Yet Assigned

Art Unit: 1627

#8
RECEIVED
MAR 06 2002
TECH CENTER 1600/2900

INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR §1.56

Commissioner for Patents
Box PATENT APPLICATION
Washington, D.C. 20231

Sir:

Applicants submit herewith on Form PTO-1449 a listing of the documents cited by the U.S. PTO on Forms PTO-892, or submitted to the U.S. PTO in parent application Serial No. 08/702,232, filed 08/23/1996. As provided in 37 CFR §1.98(d), copies of the documents are not being provided since they were previously submitted to the United States Patent & Trademark Office in the above-identified parent application.

The submission of any document herewith, which is not a statutory bar, is not intended as an admission that such document constitutes prior art against the claims of the present application or that such document is considered material to patentability as defined in 37 CFR §1.56(b). Applicants do not waive any rights to take any action which would be appropriate to antedate or otherwise remove as a competent reference any document which is determined to be a *prima facie* art reference against the claims of the present application.

TIMING OF THE DISCLOSURE

The listed documents are being submitted in compliance with 37 CFR §1.97(b), before the mailing date of the first Office Action on the merits.

RELEVANCE OF EACH DOCUMENT

The relevance of the foreign-language documents is explained in the parent application.

Applicants respectfully request that any listed document be considered by the Examiner and be made of record in the present application and that an initialed copy of Form PTO-1449 be returned in accordance with MPEP §609.

The Commissioner is hereby authorized to charge any additional fees which may be required regarding this application under 37 C.F.R. §§ 1.16-1.17, or credit any overpayment, to Deposit Account No. 19-0741. Should no proper payment be enclosed herewith, as by a check being in the wrong amount, unsigned, post-dated, otherwise improper or informal or even entirely missing, the Commissioner is authorized to charge the unpaid amount to Deposit Account No. 19-0741.

Date 3/1/02

FOLEY & LARDNER
Customer Number: 22428

22428

22428

PATENT TRADEMARK OFFICE

Telephone: (202) 672-5475
Facsimile: (202) 672-5399

Respectfully submitted,

By



Beth A. Burrous
Attorney for Applicant
Registration No. 35,087

FORM PTO-1449					ATTY. D. NO.		SERIAL NO.	
LIST OF PATENTS AND OTHER ITEMS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)					38602-1220		09/897,755	
					APPLICANT: Peng Cho Tang et al.			
					FILING DATE: 7/3/01		GROUP: 1627	

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB CLASS	TRANSLATION	
						YES	NO
AA	0 6 2 6 3 7 7	11/30/94	EPO (Haga et al.)				
AB	9 7 3 6 8 6 7	10/09/97	WO/PCT (Howard)				
AC	9 2 8 6 7 7 7	11/04/97	Japan				
AD	9 5 1 4 6 6 7	06/01/95	WO/PCT (Masamune)				
AE	3 3 1 0 8 9 1	09/27/84	Germany (Michel et al.)				
AF	3 4 2 6 4 1 9	01/23/86	Germany (Michel et al.)				
AG	9 7 2 5 9 8 6	07/24/97	WO/PCT (Sato et al.)				
AH	0 7 8 8 8 9 0	08/13/97	EPO (Vanmaele)				


OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

AI	Howard, Provisional Patent Application No. 60/015,134 filed March 29, 1996 for "Lactam Derivatives"

RECEIVED
MAR 06 2007
TECH. CENTER 1000/1200

EXAMINER:	DATE CONSIDERED:
<p>* MINER: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through if not in conformance and not considered. Include a copy of this form with next communication to applicant.</p>	

FORM PTO-1449

LIST OF PATENTS AND OTHER ITEMS FOR APPLICANT'S
INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

ATTY. DOCKET NO.

38602-1220

SERIAL NO.

09/897,755

APPLICANT:

Peng Cho Tang et al.

FILING DATE:

7/3/01

GROUP:

1627

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER							DATE	NAME	CLASS	SUB CLASS	FILING DATE
	AA	2	9	6	8	5	5	7	01/17/61	Burgardt et al.			
	AB	5	4	0	9	9	4	9	04/95	Buzzetti et al.			
	AC	5	3	9	7	7	8	7	03/14/95	Buzzetti et al.			
	AD	5	3	7	4	6	5	2	12/20/94	Buzzetti et al.			
	AE	5	1	2	4	3	4	7	06/23/92	Connor et al.			
	AF	5	3	3	0	9	9	2	07/19/94	Eissenstat et al.			
	AG	5	4	6	3	0	5	2	10/31/95	Haga et al.			
	AH	2	8	7	2	3	7	2	02/03/59	Hull			
	AI	5	2	0	6	2	6	1	04/93	Kawaguchi et al.			
	AJ	4	8	6	8	3	0	4	09/19/89	Larock et al.			
	AK	5	3	8	2	5	9	3	01/95	Le Baut			
	AL	5	2	1	7	9	9	9	06/08/93	Levitzki			
	AM	4	6	4	2	3	0	9	02/10/87	Michel et al.			
	AN	4	8	2	6	8	4	7	05/02/89	Michel et al.			
	AO	5	0	5	1	4	1	7	09/24/91	Nadler et al.			
	AP	4	9	7	1	9	9	6	11/20/90	Shiraishi et al.			
	AQ	4	8	5	3	4	0	3	08/01/89	Shiraishi et al.			
	AR	5	2	0	2	3	4	1	04/13/93	Shiraishi et al.			
	AS	5	0	5	7	5	3	8	10/15/91	Shiraishi et al.			
	AT	5	0	8	9	5	1	6	02/18/92	Shiraishi et al.			
	AU	5	3	2	2	9	5	0	06/94	Sircar et al.			
	AV	5	3	0	2	6	0	6	04/12/94	Spada et al.			
	AW	4	9	6	6	8	4	9	10/30/90	Vallee et al.			

FOREIGN PATENT DOCUMENTS


EXAMINER INITIAL		DOCUMENT NUMBER							DATE	COUNTRY	CLASS	SUB CLASS	TRANSLATION	
													YES	NO
	AX	0	5	6	6	2	6	6	15.1.93	EPO (Barker et al.)				
	AY	9	4	1	4	8	0	8	07.07.94	WO/PCT (Buzzetti et al.)				
	AZ	0	5	2	5	4	7	2	03.02.93	EPO (Buzzetti et al.)				
	BA	9	5	0	1	3	4	9	12.01.95	WO/PCT (Buzzetti et al.)				
	BB	9	6	1	6	9	6	4	06.06.96	WO/PCT (Buzzetti et al.)				
	BC	0	6	6	2	4	7	3	12.07.95	EPO (Buzzetti et al.)				

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

FORM PTO-1449

LIST OF PATENTS AND OTHER ITEMS FOR APPLICANT'S
INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

ATTY. DOCKET NO.

38602/1220

SERIAL NO.

09/897,755

APPLICANT:

Peng Cho Tang et al.

FILING DATE:

7/3/01

GROUP:

1627


	BD	9	6	0	0	2	2	6	04.01.96	WOPCT (Buzzetti et al.)			
	BE	9	5	1	7	1	8	1	29.06.95	WOPCT (Buzzetti et al.)			
	BF	9	1	1	3	0	5	5	05.09.92	WOPCT (Buzzetti et al.)			
	BG	9	3	0	1	1	8	2	21.01.93	WOPCT (Buzzetti et al.)			
	BH	9	4	0	3	4	2	7	17.02.94	WOPCT (Dobrusin et al.)			
	BI	9	2	2	1	6	6	0	10.04.92	WOPCT (Dow)			
	BJ	9	1	1	5	4	9	5	17.10.91	WOPCT (Dow et al.)			
	BK	0	5	8	0	5	0	2	01.94	EPO			
	BL		8	7	8	5	3	9	06.53	Germany			
	BM	2	6	8	9	3	9	7	08.10.93	France (Guillaume et al.)			
	BN		8	0	9	6	9	1	04.93.59	Great Britain (Hull)			
	BO	1	3	9	8	2	2	4	29.03.65	France (Imperial Chemical)			
	BP	6	2	2	9	5	7	0	07.02.87	Japan			
	BQ	6	2	3	9	5	6	4	02.87	Japan			
	BR	63	1	4	1	9	5	5	14.06.88	Japan			
	BS	9	4	1	0	2	0	2	11.05.94	WOPCT (Johnston et al.)			
	BT		2	8	6	8	7	0	04.12.64	Australia (Mumane and Moore)			
	BU	0	3	5	1	2	1	3	17.01.90	EPO (Nadler et al.)			
	BV	9	2	0	7	8	3	0	14.05.92	WOPCT (Nakanishi et al.)			
	BW	0	6	3	2	1	0	2	15.06.94	EPO (Roschger)			
	BX		5	5	8	8	9	4	09.03.93	Japan (Sakuda et al.)			
	BY	2	0	1	2	6	3	4	20.09.91	Canada (Salan)			
	BZ	2	1	5	9	3	6	0	14.06.73	Germany (Scheer et al.)			
	CA	2	1	5	9	3	6	1	14.06.73	Germany (Scheer et al.)			
	CB	2	1	5	9	3	6	2	14.06.73	Germany (Scheer et al.)			
	CC	2	1	5	9	3	6	3	14.06.73	Germany (Scheer et al.)			
	CD		8	3	5	4	7	3	18.05.60	Great Britain (Senior)			
	CE	8	8	0	7	0	3	5	22.09.88	WOPCT (Shiraishi et al.)			
	CF	9	2	0	3	7	3	6	06.05.92	WOPCT (Spada et al.)			
	CG	2	3	2	1	6	5	6	15.11.73	Germany (Tomlinson)			
	CH	1	3	8	4	5	9	9	19.02.75	Great Britain (Tomlinson)			
	CI	9	6	2	2	9	7	6	08/96	WOPCT			

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw citation if not in conformance and not considered. Include a copy of this form with next communication to


FORM PTO-1449 LIST OF PATENTS AND OTHER ITEMS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)	ATTY. DOCKET NO. 38602-1220	SERIAL NO. 09/897,755
	APPLICANT: Peng Cho Tang et al.	
	FILING DATE: 7/3/01	GROUP: 1627



OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
	CJ	Abramovitch et al., "A Novel Synthesis of a Cyclic Hydroxamic Acid Involving a Molecular Rearrangement," <u>Chemistry and Industry</u> 44:1871 (1967)
	CK	Abramovitch and Hey, "Internuclear cyclisation," <u>J. Chem. Soc.</u> pp. 1697-1703 (1954)
	CL	Akbasak and Suner-Akbasak et al., "Oncogenes: cause or consequence in the development of glial tumors," <u>J. Neurol. Sci.</u> 111:119-133 (1992)
	CM	Andreani et al., "Synthesis and cardiotonic activity of 2-indolinones," <u>Eur. J. Med. Chem.</u> 25:187-190 (1990)
	CN	Andreani et al., "Synthesis and cardiotonic activity of 2-indolinones bearing pyridyl groups," <u>Eur. J. Med. Chem.</u> 28:653-657 (1993)
	CO	Andreani et al., "Synthesis of lacatams with potential cardiotonic activity," <u>Eur. J. Med. Chem.</u> 28:825-829 (1993)
	CP	Andreani et al., "Synthesis and cardiotonic activity of pyridylmethylene-2-indolinones," <u>Eur. J. Med. Chem.</u> 27:167-170 (1992)
	CQ	Arteaga et al., "Blockade of the type I somatomedin receptor inhibits growth of human breast cancer cells in athymic mice," <u>J. Clin. Invest.</u> 84:1418-1423 (1989)
	CR	Autrey and Tahk, "The Synthesis and Stereochemistry of Some Isatylideneacetic Acid Derivatives," <u>Tetrahedron</u> 23:901-917 (1967)
	CS	Bahner et al., "Benzylideneindenes with Oxygen Attached to the Indene Ring," <u>J. Med. Chem.</u> 12:721-722 (1969)
	CT	Bamfield et al., "Diels-Alder Reactions of Oxindolylideneacetone," <u>J. Chem. Soc. (C)</u> pp. 1028-1030 (1966)
	CU	Baserga, "Oncogenes and the strategy of growth factors," <u>Cell</u> 79:927-930 (1994)
	CV	Baserga, "The insulin-like growth factor I receptor: a key to tumor growth?" <u>Cancer Res.</u> 55:249-252 (1995)
	CW	Blake and Jaques, "Anisotropic Effects in alpha-substituted methoxystilbenes," <u>J. Chem. Soc. Perkin II</u> pp. 1660-1663 (1973)
	CX	Bolen et al., "The Src family of tyrosine protein kinases in hemopoietic signal transduction," <u>FASEB J.</u> 6:3403-3409 (1992)
	CY	Bolen, "Nonreceptor tyrosine protein kinases," <u>Oncogene</u> 8:2025-2031 (1993)
	CZ	Borsche et al., "Uber nielkernige kondensierte systeme mit heterocyclischen ringen," <u>Liebigs Ann. Chem.</u> 550:160-174 (1941)
	DA	Buzzetti et al., "Cinnamamide Analogs as Inhibitors of Protein Tyrosine Kinases," <u>Il Farmaco</u> 48:615-636 (1993)
	DB	Canoira and Rodriguez, "Synthesis of Oxindole Derivatives from N-Alkenyl-o-Chloroanilides with Zero-Valent Nickel Complex," <u>J. Heterocyclic Chem.</u> 22:1511-1518 (1985)
	DC	Chatten et al., "Substituted Oxindoles. Part VI. Polargraphic Reduction of Substituted trans-3-benzylideneindol-2(3H)-ones," <u>J. Chem. Soc. Perkin II</u> pp. 469-473 (1973)
	DD	Coda et al., "(Z)- and (E)-Arylidene-1,3-dihydroindol-2-ones: Configuration, Conformation and Infrared Carbonyl Stretching Frequencies," <u>J. Chem. Soc. Perkin II</u> pp. 615-619 (1984)
	DE	Coppola et al., "A functional insulin-like growth factor I receptor is required for the mitogenic and transforming activities of the epidermal growth factor receptor," <u>Mol. Cell. Biol.</u> 14:4588-4595 (1994)


EXAMINER:	DATE CONSIDERED:
------------------	-------------------------

EXAMINER: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line thru citation if not in conformance and not considered. Include a copy of this form with next communication to applica.

FORM PTO-1449 LIST OF PATENTS AND OTHER ITEMS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT  (Use several sheets if necessary)	ATTY. DOCKET NO. 38602/1220	SERIAL NO. 09/897,755
	APPLICANT: Peng Cho Tang et al.	
	FILING DATE: 7/3/01	GROUP: 1627


	DF	Daisley, "Thin-layer chromatographic separation of some substituted 3-benzylidene-indol-2(3H)-ones," <u>J. Chromatography</u> 100:240-242 (1974)
	DG	Dati et al., "Inhibition of c-erbB-2 oncogene expression by estrogens in human breast cancer cells," <u>Oncogene</u> 5:1001-1006 (1990)
	DH	De Vries et al., "The fms-Like Tyrosine Kinase, a Receptor for Vascular Endothelial Growth Factor," <u>Science</u> 255:989-991 (1992)
	DI	Decker and Lohmann-Matthes, "A quick and simple method for the quantitation of lactate dehydrogenase release in measurements of cellular cytotoxicity and tumor necrosis factor (TNF) activity," <u>J. Immunol. Methods</u> 15:61-69 (1988)
	DJ	Dickson et al., "Tyrosine kinase receptor-nuclear protooncogene interactions in breast cancer," <u>Cancer Treatment Res.</u> 61:249-273 (1992)
	DK	Elliott and Rivers, "Reduction of some oxindolylidene derivatives to 3-substituted oxindoles by sodium borohydride," <u>J. Org. Chem.</u> 29:2438-2440 (1964)
	DL	Fantl et al., "Distinct Phosphotyrosines on a Growth Factor Receptor Bind to Specific Molecules That Mediate Different Signaling Pathways," <u>Cell</u> 69:413-423 (1992)
	DM	Fendly et al., "Characterization of Murine Monoclonal Antibodies Reactive to Either the Human or Epidermal Growth Factor Receptor or HER2/neu Gene Product" <u>Cancer Research</u> 50:1550-1558 (1990)
	DN	Ferrara and Henzel, "Pituitary Follicular Cells Secrete a Novel Heparin-Binding Growth Factor Specific for Vascular Endothelial Cells," <u>Biochem. Biophys. Res. Commun.</u> 161:851-858 (1989)
	DO	Fingl and Woodbury, Chapter 1, pp.1-46 in <u>The Pharmacological Basis of Therapeutics</u> (5th edition), eds. Goodman et al., MacMillan Publishing Co., Inc., New York (1975)
	DP	Floege et al., "Factors involved in the regulation of mesangial cell proliferation <i>in vitro</i> and <i>in vivo</i> ," <u>Kidney International</u> 43S:47-54 (1993)
	DQ	Folkman and Shing, "Angiogenesis," <u>J. Biol. Chem.</u> 267:10931-10934 (1992)
	DR	Folkman, "What is the Evidence that Tumors are Angiogenesis Dependent?" <u>Journal of the National Cancer Institute</u> 82:4-6 (1990)
	DS	Goldring, "Cytokines and cell growth control," <u>Critical Reviews in Eukaryotic Gene Expression</u> 1:301-326 (1991)
	DT	Gottardis et al., "Estradiol-Stimulated Growth of MCF-7 Tumors Implanted in Athymic Mice: A Model to Study the Tumoristatic Action of Tamoxifen," <u>J. Steroid Biochem.</u> 30(1-6):311-314 (1988)
	DU	Hewgill and Stewart, "Phenanthrene-4,5-quinones: a Synthesis of Morphenol," <u>J. Chem. Soc. Perkin Trans. I</u> pp. 1305-1311 (1988)
	DV	Hodges et al., "Chemical and biological properties of some oxindolidyl-3-methines," <u>Canadian J. Chemistry</u> 46:2189-2194 (1968)
	DW	Honegger et al., "Point Mutation at the ATP Binding Site of EGF Receptor Abolishes Protein-Tyrosine Kinase Activity and Alters Cellular Routing," <u>Cell</u> 5:199-209 (1987)
	DX	Houck et al, "Dual Regulation of Vascular Endothelial Growth Factor Bioavailability by Genetic and Proteolytic Mechanisms," <u>J. Biol. Chem.</u> 267:26031-26037 (1992)
	DY	Howard et al., "Synthesis and aldose reductase inhibitory activity of substituted 2(1H)-benzimidazolone- and oxindole-1-acetic acids," <u>Eur. J. Med. Chem.</u> 27:779-789 (1992)
	DZ	Ijaz et al., "The Conversion of α,β -Dinitrostyrenes into Indoles and the Preparation of Oxindole Quinones," <u>J. Chem. Res. (S)</u> pp. 116 (1990)

EXAMINER:	DATE CONSIDERED:
EXAMINER: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.	

FORM PTO-1449 LIST OF PATENTS AND OTHER ITEMS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT  (Use several sheets if necessary)	ATTY. DOCKET NO. 38602-1220	SERIAL NO. 09/897,755
	APPLICANT: Peng Cho Tang et al.	
	FILING DATE: 7/3/01	GROUP: 1627

	EA	Jellinek et al., "Inhibition of Receptor Binding by High-Affinity RNA Ligands to Vascular Endothelial Growth Factor," <u>Biochemistry</u> 33:10450-10456 (1994)
	EB	Katritzky et al., "Color and Constitution. Part 8[1]. Some Novel Dyestuffs Containing Indoxyl Residues," <u>J. Heterocyclic Chem.</u> 25:1287-1292 (1988)
	EC	Kendall and Thomas, "Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble-receptor," <u>Proc. Natl. Acad. Sci. USA</u> 90:10705-10709 (1993)
	ED	Khalil and Abdel-Rahman, "Synthesis of New Mero- and Asymmetrical Pyrazolo-Monomethine Cyanine Dyes," <u>J. Indian Chem. Soc.</u> 54:904-907 (1977)
	EE	Kim et al., "Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth <i>in vivo</i> ," <u>Nature</u> 362:841-844 (1993)
	EF	Kinsella et al., "Protein Kinase C Regulates Endothelial Cell Tube Formation on Basement Membrane Matrix, Matrigel," <u>Exp. Cell Research</u> 199:52-62 (1992)
	EG	Klagsbrun and Soker, "VEGF/VPF: the angiogenesis factor found?" <u>Current Biology</u> 3:699-702 (1993)
	EH	Kobayashi et al., "Anti-tumor Activity of Indole Derivatives," <u>Yakugaku Zasshi</u> 97(9):1033-1039 (1977)
	EI	Koch et al., "SH2 and SH3 Domains: Elements That Control Interactions of Cytoplasmic Signaling Proteins," <u>Science</u> 252:668-674 (1991)
	EJ	Korc et al., "Overexpression of the epidermal growth factor receptor in human pancreatic cancer is associated with concomitant increases in the levels of epidermal growth factor and transforming growth factor alpha," <u>J. Clin. Invest.</u> 90:1352-1360 (1992)
	EK	Korzeniewski and Callewaert, "An Enzyme-Release Assay for Natural Cytotoxicity ¹ ," <u>J. Immunol. Methods</u> 64:313-320 (1983)
	EL	Kovac and Stetinova, "Furan derivatives LXXX. Synthesis and properties of substituted furfurylidenoxindoles," <u>Chem. rvesu</u> 30:484-492 (1976)
	EM	Kumbar et al., "Amplification of alpha-platelet-derived growth factor receptor gene lacking an exon coding for a portion of the extracellular region in a primary brain tumor of glial origin," <u>Oncogene</u> 7:627-633 (1992)
	EN	Larock and Babu, "Synthesis of Nitrogen Heterocycles via Palladium-catalyzed Intramolecular Cyclization," <u>Tetrahedron Letters</u> 28:52991-5294 (1987)
	EO	Lee and Donoghue, "Intracellular retention of membrane-anchored v-sis protein abrogates autocrine signal transduction," <u>J. Cell. Biol.</u> 118:1057-1070 (1992)
	EP	Macauley et al., "Autocrine function for insulin-like growth factor I in human small cell lung cancer cell lines and fresh tumor cells," <u>Cancer Res.</u> 50:2511-2517 (1990)
	EQ	Mariani et al., "Inhibition of angiogenesis by PCE 26806, a potent tyrosine kinase inhibitor," <u>Experimental Therapeutics - Proceedings of the American Association for Cancer Research</u> 35:301 at abstract no. 2268 (March 1994)
	ER	Martin-León et al., "On the Cyclization to the Elusive Amino-4H-pyran Ring," <u>Liebigs Ann. Chem.</u> pp. 101-104 (1990)
	ES	Mirand et al., "A Synthetic Entry in the Aristotelia Alkaloids," <u>J. Org. Chem.</u> 47:4169-4170 (1982)
	ET	Mosmann, "Rapid Colorimetric Assay for Cellular Growth and Survival: Application to Proliferation and Cytotoxicity Assays," <u>J. Immunol. Methods</u> 65:55-63 (1983)
	EU	Neber and Rocker, "Ueber die einwirkung von benzaldehyden auf die freie o-aminophenyl-essigsäure," <u>Chem. Ber.</u> 56:1710-1717 (1923)


EXAMINER:	DATE CONSIDERED:
EXAMINER: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.	

FORM PTO-1449 LIST OF PATENTS AND OTHER ITEMS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary) 	ATTY. DOCKET NO. 38602-1220	SERIAL NO. 09/897,755
	APPLICANT: Peng Cho Tang et al.	
	FILING DATE: 7/3/01	GROUP: 1629

EV	Nodiff et al., "Antimalarial Phenanthrene Amino Alcohols. 1. Fluorine-Containing 3- and 6-Substituted 9-Phenanthrenemethanols," <u>J. Med. Chem.</u> 14:921-925 (1971)
EW	O'Sullivan and Rothery, "The Preparation and Possible Clinical Significance of 4'-Dialkylaminoisoindogenides," <u>Clinica Chimica Acta</u> 62:181-182 (1975)
EX	Osborne et al., "Effect of Estrogens and Antiestrogens on Growth of Human Breast Cancer Cells in Athymic Nude Mice," <u>Cancer Research</u> 45:584-590 (1985)
EY	Ozzello and Sordat, "Behavior of Tumors Produced by Transplantation of Human Mammary Cell Lines in Athymic Nude Mice," <u>Eur. J. Cancer</u> 16:553-559 (1980)
EZ	Pavlenko et al., "Introduction of aminomethyl groups into heterocyclic CH-acid molecules," <u>Dopov. Akad. Nauk Ukr, RSR</u> 7:64-66 (1980)
FA	Plate, "Vascular endothelial growth factor is potential tumor angiogenesis factor in human gliomas <i>in vivo</i> ," <u>Nature</u> 359:845-848 (1992)
FB	Plowman et al., "Receptor Tyrosine Kinases as Targets for Drug Intervention," <u>DN&P</u> 7(6):334-339 (1994)
FC	Rueda and Gonzalez, "Geometric isomerism in benzylideneoxindoles," <u>Spectrochimica Acta</u> 26A:1275-1277 (1970)
FD	Rygaard and Povlsen, "Heterotransplantation of a Human Malignant Tumour to 'Nude' Mice," <u>Acta path. microbiol. scand.</u> 77:758-760 (1969)
FE	Sandberg-Nordqvist et al., "Characterization of insulin-like growth factor 1 in human primary brain tumors," <u>Cancer Res.</u> 53:2475-2478 (1993)
FF	Schindler et al., "Über Dibenz[b,f]-azocin-Derivate," <u>Helvetica Chimica Acta</u> 49:985-989 (1966)
FG	Schlessinger and Ullrich, "Growth Factor Signalling by Receptor Tyrosine Kinases," <u>Neuron</u> 9:383-391 (1992)
FH	Schnierle et al., "Vilsmeier-Reaktion mit Pyrrol- und Pyrrolon-Derivaten," <u>Liebigs Ann. Chem.</u> 715:90-97 (1968)
FI	Schuchter et al., "Successful Treatment of Murine Melanoma with Bryostatin 1," <u>Cancer Research</u> 51:682-687 (1991)
FJ	Seibert et al., "Clonal Variation of MCF-7 Breast Cancer Cells <i>in Vitro</i> and in Athymic Nude Mice," <u>Cancer Research</u> 43:2223-2239 (1983)
FK	Shafie and Grantham, "Role of Hormones in Growth and Regression of Human Breast Cancer Cells (MCF-7) Transplanted into Athymic Nude Mice," <u>J. Natl. Cancer Institute</u> 67(1):51-56 (1981)
FL	Shibuya et al., "Nucleotide sequence and expression of a novel human receptor-type tyrosine kinase gene (<i>flt</i>) closely related to the <i>fms</i> family," <u>Oncogene</u> 5:519-524 (1990)
FM	Shiraishi, "Specific inhibitors of Tyrosine-Specific Protein Kinase, Synthetic 4-Hydroxycinnamamide Derivatives," <u>Biochemical and Biophysical Research Communications</u> 147:322-328 (1987)
FN	Shiraishi et al., "Specific Inhibitors of Tyrosine-specific Protein Kinases: Properties of 4-Hydroxycinnamamide Derivatives <i>in Vitro</i> ," <u>Cancer Research</u> 49:2374-2378 (1989)
FO	Shweiki, "Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis," <u>Nature</u> 359:843-845 (1992)
FP	Skehan et al., "New Colorimetric Cytotoxicity Assay for Anticancer-Drug Screening," <u>J. Natl. Cancer Inst.</u> 82:1107-1112 (1990)
FQ	Slamon et al., "Studies of the HER-2/ <i>neu</i> Proto-oncogene in Human Breast and Ovarian Cancer," <u>Science</u> 244:707-712 (1989)


EXAMINER:	DATE CONSIDERED:
EXAMINER: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.	

FORM PTO-1449 LIST OF PATENTS AND OTHER ITEMS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)	ATTY. DOCKET NO. 38602-1220	SERIAL NO. 09/897,755
	APPLICANT: Peng Cho Tang et al.	
	FILING DATE: 7/3/01	GROUP: 1627



FR	Songyang et al., "Specific motifs recognized by the SH2 domains of Csk, 3BP2, fps/fes, GRB-2, HCP, SHC, Syk and Vav," <u>Molecular and Cellular Biology</u> 14:2777-2785 (1994)
FS	Songyang et al., "SH2 Domains Recognize Specific Phosphopeptide Sequences," <u>Cell</u> 72:767-778 (1993)
FT	Stetinova et al., "Stereochemistry and Photoisomerisation of Furfurylideneoxindoles," <u>Collection Czechoslov. Chem. Commun.</u> 42:2201-2206 (1976)
FU	Sumpter and Miller, "Chapter IV - Oxindole," in <u>Heterocyclic Compounds With Indole and Carbazole Systems</u> , Interscience Publishers, Inc., New York, pp. 134-153 (1954)
FV	Tacconi et al., "(Z)- and (E)-3-Alkylidene-1,3-dihydroindol-2-ones: Influence of Configuration on the Transmission of the Inductive Effect to the Carbonyl Group," <u>J.C.S. Perkin II</u> pp. 150-154 (1976)
FW	Tacconi and Marinone, "Preparazione e caratteristiche di alcuni 3-ossindolidenderivati," <u>Ricerca Scientifica</u> 38:1239-1244 (1968)
FX	Takano et al., "Inhibition of angiogenesis by a novel diaminoanthraquinone that inhibits protein kinase C," <u>Mol. Bio. Cell</u> 4:358A (1993)
FY	Thompson et al., "Facile Dimerisation of 3-Benzylideneindoline-2-thiones," <u>J. Chem. Soc. Perkin Trans. (I)</u> pp. 1835-1837 (1993)
FZ	Torp et al., "Expression of the epidermal growth factor receptor gene in human brain metastases," <u>AMPIS</u> 100:713-719 (1992)
GA	Triebbs et al., "Über isoindigoide Farbstoffe der Pyrrol-Reihe," <u>Liebigs Ann. Chem.</u> 702:112-130 (1967)
GB	Tuzi et al., "Expression of growth factor receptors in human brain tumours," <u>Br. J. Cancer</u> 63:227-233 (1991)
GC	Ullrich and Schlessinger, "Signal Transduction by Receptors with Tyrosine Kinase Activity," <u>Cell</u> 61:203-212 (1990)
GD	Vaisman et al., "Characterization of the Receptors for Vascular Endothelial Growth Factor," <u>J. Biol. Chem.</u> 265:19461-19466 (1990)
GE	Varma and Gupta, "Nucleophilic Reactions of 2-Methyl-3-(4'-carbomethoxyphenyl)-4-quinazolinones with 2-Indolinones," <u>J. Indian Chem. Soc.</u> 66:804-805 (1989)
GF	Voller et al., "Enzyme-Linked Immunosorbent Assay," in <u>Manual of Clinical Immunology</u> , 2nd edition, Rose and Friedman editors, American Society of Microbiology, Washington, D.C., pp. 359-371 (1980)
GG	von Dobeneck et al., " α,β' -Diindolylmethane und -methene. Der Urorosein-Chromophor," <u>Zur Chemie des Indols VI</u> :1347-1357 (1969)
GH	Wahl et al., "Chimie Organique - Sur les iso-indogenides," <u>C.R. Hebd. Seances Acad. Sci.</u> 149:132-134 (July 1909)
GI	Walker, "Synthesis of New 3-(Pyridylmethylene)-, 3-(Pyridylmethyl)-, 3-(Piperidylmethyl)-, and 3-(β -Alkylaminoethyl)-2-indolinones. The Reduction of Isoindogenides, Nitro Compounds, and Pyridines in a Series of 2-Indolinones," <u>J. Med. Chem.</u> 8(5):626-637 (1965)
GJ	Walker, "Synthesis of a α -(p-Aminophenyl)- and α -(p-Chlorophenyl)- β -aryl-propionitriles by Catalytic Reduction of Stilbenenitriles," <u>J. Med. Chem.</u> 8(5):583-588 (1965)
GK	Warri et al., "Estrogen Suppression of <i>erbB2</i> Expression is Associated with Increased Growth Rate of ZR-75-1 Human Breast Cancer Cells <i>In Vitro</i> and in Nude Mice," <u>Int. J. Cancer</u> 49:616-623 (1991)
GL	Weidner et al., "Tumor Angiogenesis and Metastasis - Correlation in Invasive Breast Carcinoma," <u>New England J. Medicine</u> 324:1-7 (1991)

EXAMINER:	DATE CONSIDERED:
EXAMINER: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through	

FORM PTO-1449 LIST OF PATENTS AND OTHER ITEMS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary) 	ATTY. DOCKET NO. 38602-1220	SERIAL NO. 09/897,755
	APPLICANT: Peng Cho Tang et al.	
	FILING DATE: 7/3/01	GROUP: 1627

	GM	Winkelmann et al., "Chemotherapeutically Active Nitro Compounds: 4. 5-Nitroimidazoles (Part I)," <u>Arzneim.-Forsch./Drug Res.</u> 27(II):2251-2263 (1977)
	GN	Wright et al., "Cyclic Hydroxamic Acids Derived from Indole," <u>JACS</u> 78:221-224 (1956)
	GO	Wright et al., "Inhibition of Angiogenesis in Vitro and In Ovo With an Inhibitor of Cellular Protein Kinases, MDL 27032," <u>J. Cellular Physiology</u> 152:448-457 (1992)
	GP	Young and Babbitt, "2-(2-Methyl-3-indolyl)-1,4-benzoquinone, a Reversible Redox Substrate at the Carbon Paste Electrode in Acidic Aqueous-Ethanol Media," <u>J. Org. Chem.</u> 47:1571-1572 (1982)
	GQ	Zhungietu et al., "Reaction of Indoles and 2-Ketoindolines With Some Aldehydes," <u>Institute of Chemistry, Academy of Science of the Moldavian SSR, Kishinev</u> pp. 34-37 translated from <u>Khimiya Geterotsiklicheskikh Soedinenii</u> 1:40-44 (1973)

EXAMINER:	DATE CONSIDERED:
EXAMINER: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.	


FORM PTO-1449		ATTY. DOCKET NO. 38602-1220	SERIAL NO. 09/897,753
LIST OF PATENTS AND OTHER ITEMS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		APPLICANT: Peng Cho Tang et al.	
		FILING DATE: 7/3/01	GROUP: 1627

U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE

FOREIGN PATENT DOCUMENTS								
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB CLASS	TRANSLATION	
							YES	NO
	AA	WO 99/10325	04.03.99	PCT (McNutt et al.)				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
	AB	Andreani et al., "In Vivo Cardiotoxic Activity of Pyridylmethylene-2-indolinones," <u>Arzneimittel-Forschung Drug Research</u> 48(II):727-729 (1998)
	AC	Carpenedo et al., "Identification and Measurement of Oxindole (2-Indolinone) in the Mammalian Brain and Other Rat Organs," <u>Analytical Biochemistry</u> 244:74-79 (1997)
	AD	Chen et al., "Effects of 3,3-Dipyridylmethyl-1-Phenyl-2-Indolinone on γ -Aminobutyric Acid Elicited Chloride Current of Snail Central Neuron," <u>Chinese Journal of Physiology</u> 40(3):149-156 (1997)
	AE	Damiani et al., "Inhibition of Copper-Mediated Low Density Lipoprotein Peroxidation by Quinoline and Indolinone Nitroxide Radicals," <u>Biochemical Pharmacology</u> 48(6):1155-1161 (1994)
	AF	Davis et al., "Synthesis and Microbiological Properties of 3-Amino-1-Hydroxy-2-Indolinone and Related Compounds," <u>Journal of Medicinal Chemistry</u> 16(9):1043-1045 (1973)
	AG	Graziani et al., "Hepatocyte Growth Factor/Scatter Factor Stimulates the Ras-Guanine Nucleotide Exchanger*," <u>The Journal of Biological Chemistry</u> 268(13):9165-9168 (1993)
	AH	Kato et al., "Simultaneous Determination of Amfenac Sodium and its Metabolite (7-Benzoyl-2-Oxindole) in Human Plasma by High-Performance Liquid Chromatography," <u>Journal of Chromatography</u> 616:67-71 (1993)
	AI	Maass et al., "Viral Resistance to the Thiazolo-Iso-Indolinones, a New Class of Nonnucleoside Inhibitors of Human Immunodeficiency Virus Type 1 Reverse Transcriptase," <u>Antimicrobial Agents and Chemotherapy</u> 37(12):2612-2617 (1993)
	AJ	Moreto et al., "3,3-Bis-(4-Hydroxyphenyl)-7-Methyl-2-Indolinone (BHMI), the Active Metabolite of the Laxative Sulisatin," <u>Arzneimittel-Forschung Drug Research</u> 29(II):1561-1564 (1979)
	AK	Moreto et al., "Study of the Laxative Properties of the Disodium Salt of the Sulfuric Diester of 3,3 Bis-(4-Hydroxyphenyl)-7-Methyl-2-Indolinone (Dan-603) in the Rat," <u>European Journal of Pharmacology</u> 36:221-226 (1976)
	AL	Singh et al., "Indolinone Derivatives as Potential Antimicrobial Agents," <u>Zentralbl. Mikrobiol.</u> 144:105-109 (1989)
	AM	Singh et al., "Synthesis and Anticonvulsant Activity of New 1-Substituted 1'-Methyl-3-Chloro-2-Oxosprio (Azetidin-3', 4-Indol-2' Ones)," <u>Bollettino Chimico Farmaceutico</u> 133:76-79 (1994)

EXAMINER:	DATE CONSIDERED:
EXAMINER: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.	

FORM PTO-1449 LIST OF PATENTS AND OTHER ITEMS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary) 	ATTY. DOCKET NO. 38602-1220	SERIAL NO. 09/897,755
	APPLICANT: Peng Cho Tang et al.	
	FILING DATE: 7/3/01	GROUP: 1627

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
	AN	Soldi et al., "Platelet-Activating Factor (PAF) Induces the Early Tyrosine Phosphorylation of Focal Adhesion Kinase (p125 ^{FAK}) in Human Endothelial Cells," <u>Oncogene</u> 13(3):515-525 (1996)
	AO	Tsai et al., "The Effect of 3,3-Di-Pyridyl -Methyl-1-Phenyl-2-Indolinone on the Nerve Terminal Currents of Mouse Skeletal Muscles," <u>Neuropharmacology</u> 31(9):943-947 (1992)
	AP	Zaman et al., "Tyrosine Kinase Activity of Purified Recombinant Cytoplasmic Domain of Platelet-Derived Growth Factor β -Receptor (β -PDGFR) and Discovery of a Novel Inhibitor of Receptor Tyrosine Kinases," <u>Biochemical Pharmacology</u> 57(1):57-64 (1999)
	AQ	Zhang et al., "Microtubule Effects of Welwistatin, a Cyanobacterial Indolinone that Circumvents Multiple Drug Resistance," <u>Molecular Pharmacology</u> 49:228-294 (1996)

RECEIVED
 MAR 06 2002
 TECH CENTER 1600/2900

EXAMINER:	DATE CONSIDERED:
EXAMINER: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.	



FORM PTO-1449	ATTY. DCK	SERIAL NO.
LIST OF PATENTS AND OTHER ITEMS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)	38602-1220	09/897,755
	APPLICANT: Peng Cho Tang et al.	
	FILING DATE: 7-3-01	GROUP: 1627

TECH CENTER 16002900

MAR 06 2002

RECEIVED

U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS								
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB CLASS	TRANSLATION	
							YES	NO
	AL	WO 96/32380	10/17/96	WO/PCT (Battistini)				
	AM	WO 96/22976	08/01/96	WO/PCT (Buzzetti)				
	AN	WO 96/40116	12/19/96	WO/PCT (Tang)				
	AO							
	AP							

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
	AQ	Andreani et al., "Potential Antitumor Agents. 25[1]. Synthesis and Cytotoxic Activity of 3-(2-Chloro-3-Indolylmethlene) 1,3-Dihydroindol-2-Ones," <u>AntiCancer Research</u> 16:3585-3588 (1996)
	AR	Terrett et al., "Combinatorial Synthesis-The Design of Compound Libraries and their Application to Drug Discovery," <u>Tetrahedron</u> 51(30):8135-8173 (1995)
	AS	Coda et al., "3-(4-methylbenzilidene)-1-,3-dihydroindol-2-one," <u>Journal of the Chemical Society. Perkin Transactions 2</u> 4:615-620 (1984), DATABASE CROSSFIRE, Beilstein No. 6-21
	AT	Wahl, "3-benzilidene-5-methyl-1,3-dihydroindol-2-one," <u>Ann. Chim</u> p. 350 (1926), DATABASE CROSSFIRE, Beilstein No. 2-21-00-00290
	AU	Elliot, "1-methyl-2-(3-oxindolidenmethyl)-pyridinium," <u>Journal of Organic Chemistry</u> 29:2438-2440 (1964), DATABASE CROSSFIRE, Beilstein No. 5-24
	AV	

EXAMINER:	DATE CONSIDERED:
EXAMINER: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.	

FORM PTO-1449 LIST OF PATENTS AND OTHER ITEMS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)	ATTY. DOC. NO. 38602-1220	SERIAL NO. 09/897,755
	APPLICANT: Peng Cho Tang et al.	
	FILING DATE: 7-3-01	GROUP: 162



RECEIVED
 MAR 06 2002

U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS								
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB CLASS	TRANSLATION	
							YES	NO
	AL	0 632 102	04/01/95	EPO (Roschger)			X	
	AM	WO 97/25986	07/24/97	WO/PCT (Sato)			X	
	AN							
	AO							
	AP							

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
	AQ		
	AR		
	AS		
	AT		
	AU		
	AV		
	AW		
	AX		
	AY		
	AZ		

EXAMINER:	DATE CONSIDERED:
EXAMINER: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.	

1627

(Use several sheets if necessary)

~~MAR 01 2002~~

[illegible][illegible][illegible]

EXAMINER: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.


Page 1 of 1

RECEIVED

MAR 06 2002

TECH CENTER 1600/2900

FORM PTO-1449 LIST OF PATENTS AND OTHER ITEMS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)	ATTY. Docket NO.	SERIAL NO.
	38602-1220	09/897,755
	APPLICANT: Peng Cho Tang et al.	
	FILING DATE: 7-3-01	GROUP: 1627



U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE

FOREIGN PATENT DOCUMENTS								
EXAMI NER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB CLASS	TRANSLA- TION	
							YES	NO

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)		
	AA	Andreani et al., "Synthesis and potential coanthracyclinic activity of substituted 3-(5-imidazo [2,1-b] thiazolylmethylene)-2-indolinones," <u>Eur. J. Med. Chem.</u> 32:919-924 (1997)

RECEIVED
 MAR 06 2002
 TECH CENTER 1600/2900


EXAMINER:	DATE CONSIDERED:
EXAMINER: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include a copy of this form with next communication to applicant	

Form PTO-1449 (MODIFIED)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 038602-1220		SERIAL NO. 09/897,755		
INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)				APPLICANT Peng-Cho TANG, et al.				
				FILING DATE 07/03/2001		GROUP ART UNIT 1627 USPTO_ART_UNIT01		
U.S. PATENT DOCUMENTS								
	EXAMINER INITIAL	REF	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE
			5,886,020	3/23/99	Tang et al.			
			5,792,783	8/11/99	Tang et al.			
			5,883,116	3/16/99	Tang et al.			
			5,883,113	3/16/99	Tang et al.			
			5,880,141	3/23/99	Tang et al.			
			5,409,903	4/25/95	Spada et al.			
			5,196,446	3/23/93	Levitzki Al			
			5,322,590	6/21/94	Sircar et al.			
FOREIGN PATENT DOCUMENTS								
	REF	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES NO	
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)								
		Carey, F.A. and Sundberg, R.J., "Reaction and Synthesis," <u>Advanced Organic Chemistry, Part B</u> 3 rd edition: 55-60; Plenum Press						
		March, J.; <u>Advanced Organic Chemistry</u> , 4 th edition; 109-111 and 127-130; John Wiley & Sons						
		Gordon, E.M. et al., "Application of Combinatorial Technologies to Drug Discovery. 2. Combinatorial Organic Synthesis, Library Screening Strategies, and Future Directions," <u>J. Medicinal Chemistry</u> 37:10, 1385-1401						
EXAMINER					DATE CONSIDERED			
* EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include any copy of this form with next communication to applicant.								

 RECEIVED
 MAR 06 2002
 TECH CENTER 1600/2900

Form PTO-1449 U.S. DEPARTMENT OF COMMERCE
(MODIFIED) PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO. 38602-1220		SERIAL NO. 09/897,755
APPLICANT Tang, et al.		
FILING DATE 7-3-01	GROUP ART UNIT 1627	



INFORMATION DISCLOSURE CITATION

Use several sheets if necessary)

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	REF	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE IF APPROPRIATE
	A1	5,565,324	Oct. 15, 1996	Still, et al.	435	6	Apr 13, 1994
	A2	4,053,613	Oct 11, 1977	Rovnyak, et al.	424	246	Sep 17, 1975
	A3	4,002,749	Jan 11, 1977	Rovnyak	424	246	Aug 12, 1975

FOREIGN PATENT DOCUMENTS

	REF	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION	
							YES	NO
	A4	WO 98 07695 A	Feb 26, 1998	Europe			X	

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

RECEIVED
MAR 06 2002
TECH CENTER 1600/2900

EXAMINER	DATE CONSIDERED
----------	-----------------

* EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include any copy of this form with next communication to applicant.